1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022

Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022

  • December 2016
  • 190 pages
  • ID: 4539010
  • Format: PDF
  • By Kuick Research

Summary

Table of Contents

“Global Oncolytic Virus Therapy Market & Pipeline Outlook 2022” report analyzes ongoing clinical and non-clinical trends in the oncolytic virus therapy market. Currently there are 2 oncolytic virus therapies commercially available in the market. This report analyzes the ongoing clinical trial of 48 oncolytic virus therapies in clinical pipeline and gives comprehensive clinical insight on various parameters associated with the development of the oncolytic virus therapies. Most of the oncolytic virus therapy in clinical trials are in preclinical phase followed by Phase-I trials.

The preceding decades have shown the higher incidence and prevalence trends for the cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year. Thousands of regimens have been employed for the eradication of this deadly disease and yet the new interventions are anticipated. Undeniably, several modalities have resulted in some form of relief so far, but the triumph towards cancer abolition is long way road.

The conventional chemotherapy and radiotherapy have limited therapeutic index and a plethora of treatment associated negative effects. The current scenario of the oncological treatment represents the impetus search for the novel therapeutic modalities that can selectively disrupt the tumor cells and block the cancer growth along with the safety, that the treatment will be harmless towards the normal cells.

The major role of developing the new therapy for the treatment of cancer is to have broader therapeutic index which represents the high potency towards the malignant cells with low or no toxicities towards healthy cells. One such approach is the use of the viruses for the treatment of cancer turning into term known as viral oncotherapy. With the advances in oncology and the virology, the routes towards the engineering of viruses with increased tumor selectivity and enhanced oncolytic activity is conceivable.

Therefore the oncolytic virus is a virus that preferentially infects and kills cancer cells, as the infected cancer cells are destroyed by oncolysis, they release new infectious viral particles to help destroy the remaining tumor. Oncolytic viruses perform the dual functions they not only cause the destruction of cancerous cell but also stimulate the host anti-tumor immune responses and don’t allow the growth of tumor cells. Certainly, targeted therapy of cancer using viruses has generated interest in the light of limited efficacy of the standard cancer therapeutics.

The next few years will see progress in terms of viral delivery, in particular the use of immune cell carriers that have yet to enter clinical trials. The promising strategy of combining existing antitumor adoptive cellular therapy with oncolytic viral delivery is likely to be explored. Combinations of viral therapy with chemotherapy, radiotherapy, transient immunosuppression and other immunotherapy strategies will probably be tested in early phase clinical trials.

For the broader future of oncolytic immunotherapy, it is expected that a rapid expansion of the number of clinical trials already being conducted combining this with immune co-inhibitory pathway blockade, improved oncolytic agents being developed (i.e. with greater direct antitumor effects and with an improved ability to spread through tumors), and in particular the ability of viruses to deliver proteins directly to the tumor microenvironment to help further induce, enhance, and shape the anti-tumor immune response being exploited to a greater extent.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.

ref:plp2016

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on